

2025 withdrawal proposal for pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma (TA306)

Consultation

Topic areas

- Multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma.

Withdrawal proposal

We propose to withdraw the NICE technology appraisal (TA) guidance on [pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma](#) (TA306) in line with section 8.2.19 of the [NICE health technology evaluations manual](#).

Methods

The withdrawal surveillance review process consisted of:

- Considering whether the conditions under which NICE should withdraw TA guidance as stated in section 8.2.19 of the [NICE health technology evaluations manual](#) are met.
- Considering the availability of NICE guidance and other UK guidance and support.
- Considering the implications of withdrawing the TA in terms of system impact; population impact; health inequalities; budget impact; and NICE organisational needs.

Basis for the withdrawal proposal

Pixantrone for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma (TA306) no longer has a marketing authorisation in the UK.

Withdrawal proposal – pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma (TA306)

Relevant NICE guidance

- [Non-Hodgkin's lymphoma: diagnosis and management](#) (NG52)

This guideline does not currently include pixantrone.

Other relevant UK guidance and support

There are no UK guidelines that currently recommend pixantrone.

System impact

NICE system intelligence on drug usage indicates that pixantrone is not widely used in the UK. The marketing authorisation expired in June 2024 and the manufacturer chose not to renew due to low demand.

Population impact

There is not anticipated to be any population impact of withdrawing TA306 as the technology no longer has a UK marketing authorisation and therefore is not used in the NHS.

Health inequalities

No health inequalities were identified with withdrawing this TA.

Budget impact

No budget impact implications were identified with withdrawing this TA.

Overall proposal

We propose to withdraw the NICE TA guidance on [pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma](#) (TA306) as it no longer has marketing authorisation in the UK.

Withdrawal proposal – pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma (TA306)